C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 9/48 (2006.01) A61K 38/43 (2006.01) A61K 38/47 (2006.01) A61K 38/48 (2006.01) A61K 38/55 (2006.01) A61K 39/395 (2006.01) C07K 14/42 (2006.01) C07K 14/745 (2006.01) C07K 16/36 (2006.01) C12N 9/64 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2132518
2132518 9318782 PCTABS00025 Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an .alpha.2-6 linkage are able to inhibit the conversion of human Factor X to human Factor Xa. These reagents (SA/Gal/GalNAc binding reagents) as well as other strategies for inhibiting the conversion of Factor X to Factor Xa are useful in treating thrombosis, inflammation and other conditions associated with excess thrombin activity.
Sinha Uma
Wolf David L.
Fetherstonhaugh & Co.
Millennium Pharmaceuticals Inc.
LandOfFree
Glycosylation-mediated inhibition of factor x does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycosylation-mediated inhibition of factor x, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosylation-mediated inhibition of factor x will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1932304